Background Mutant KRAS-induced tumorigenesis is prevalent in lung, colon, and pancreatic
ductal adenocarcinomas. For the past 3 decades, KRAS mutants seem undruggable due to …

Inherent or acquired resistance to sotorasib poses a substantialt challenge for NSCLC
treatment. Here, we demonstrate that acquired resistance to sotorasib in isogenic cells …

KRAS G12C inhibitors such as sotorasib and adagrasib are often effective in KRAS G12C–
driven non–small cell lung cancer (NSCLC) patients. However, acquired resistance limits …

Background Targeted therapy has revolutionized cancer treatment, greatly improving patient
outcomes and quality of life. Lung cancer, specifically non-small cell lung cancer, is …

The Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutation is prevalent in lung
adenocarcinoma (LUAD), driving tumor progression and indicating a poor prognosis. While …

Abstract Purpose: Treatment with KRAS G12C inhibitors such as sotorasib can produce
substantial regression of tumors in some patients with non–small cell lung cancer (NSCLC) …

Efforts to improve the anti-tumor response to KRAS G12C targeted therapy have benefited
from leveraging combination approaches. Here, we compare the anti-tumor response …

KRAS mutations drive oncogenic alterations in numerous cancers, particularly in human
pancreatic ductal adenocarcinoma (PDAC). About 93% of PDACs have KRAS mutations …

KRAS mutations are one of the most frequent activating alterations in carcinoma. Recent
efforts have witnessed a revolutionary strategy for KRAS G12C inhibitors with exhibiting …

KRAS is one of the most commonly mutated oncogenes in cancers and therapeutics directly
targeting the KRas have been challenging. Among the different known mutants, KRas G12C …